

TABLE OF CONTENTS

ACKNOWLEDGMENT	I
SUMMARY	III
LIST OF ABBREVIATIONS	IV
TABLE OF CONTENTS	IX
1 INTRODUCTION	1
1.1 Tuberculosis	1
1.1.1 Epidemiology	1
1.1.2 TB pathogenesis	4
1.1.3 Microbial infection	6
1.2 <i>Mycobacterium spp.</i>	7
1.2.1 <i>Mycobacterium spp.</i> genomes	8
1.2.2 <i>Mycobacterium spp.</i> virulent genes	9
1.2.3 <i>Mycobacterium spp.</i> cell wall and virulence	9
1.2.4 <i>Mycobacterium spp.</i> secretion system and virulence	17
1.2.5 Metabolism in the host cell	20
1.3 Treatment of tuberculosis	20
1.4 Drug resistance of <i>Mycobacterium tuberculosis</i>	25
1.4.1 Cell wall impermeability	25
1.4.2 Specific inhibition mechanisms	26
1.5 PDIM and PGL biosynthesis	27
1.6 Specific proteins involved in PDIM and PGL biosynthesis	32
1.6.1 <i>M. tuberculosis</i> thioesterase A (TesA)	32
1.6.2 Polyketide PpsE	35
1.6.3 Chaperonins	37
1.6.3.1 <i>E. coli</i> GroEL-GroES system	37
1.6.3.2 <i>M. tuberculosis</i> GroEL-GroES system	43
1.6.3.2.1 GroEL1 and GroEL2	43
1.6.3.2.2 GroEL1 and GroEL2 structure	46
1.6.3.2.3 GroEL1 and GroEL2 ATPase activity	50
1.6.3.2.4 GroEL1 DNA binding activity	50

2	OBJECTIVES	51
3	MATERIALS AND METHODS	52
3.1	Materials	52
3.1.1	Bacteria.....	52
3.2	Methods	52
3.2.1	Medium preparation	52
3.2.1.1	Middlebrook 7H9 Broth.....	52
3.2.1.2	Sauton's medium	52
3.2.1.3	Lysogeny broth (LB)/agar medium	52
3.2.2	Bacteria culture.....	53
3.2.2.1	<i>Mycobacterium bovis</i> BCG culture.....	53
3.2.2.2	<i>Escherichia coli</i> culture	53
3.2.2.3	Chemically competent bacteria preparation (CaCl ₂ treatment) 53	
3.2.3	Plasmid constructions.....	53
3.2.3.1	DNA extraction and concentration	54
3.2.3.2	pET-15b vector modification	54
3.2.3.3	Transformation of competent cell	57
3.2.3.4	pET-GroEL1 and pET-GroEL1ΔHis plasmid correction	57
3.2.3.5	pMtGroEL1 and pMtGroEL1ΔHis plasmid construction	59
3.2.3.6	pMtTesA plasmid construction	61
3.2.3.7	pMtGroEL2 plasmid construction	62
3.2.3.8	pMtGroES plasmid construction	63
3.2.3.9	pMtLsr2 plasmid construction	64
3.2.3.10	pMtPpsE plasmid construction	65
3.2.3.11	Chemical transformation of competent <i>E. coli</i> BL21(DE3) strain	66
3.2.4	Protein production	66
3.2.4.1	Preliminary experiment to set-up optimal condition for protein production	66
3.2.4.2	Protein production.....	67
3.2.5	Protein purification.....	67
3.2.6	SDS-PAGE, Western blot and immunodetection	69
3.2.7	Mass spectrometry analysis.....	70
3.2.7.1	Intact mass determination	70

3.2.7.2	In-gel and in solution digestions	70
3.2.7.3	Native mass spectrometry	71
3.2.8	Biochemical characterization of protein.....	72
3.2.8.1	Protein thioesterase and esterase activity assays	72
3.2.8.2	TesA potential inhibitor screening.....	73
3.2.8.3	Protein thermal stability assay	73
3.2.8.4	Oligomeric state determination.....	74
3.2.8.5	Analysis of TesA-MAFP interaction	75
3.2.8.6	TesA overexpression in <i>Mycobacterium bovis</i> BCG.....	76
3.2.8.7	Biofilm growth of <i>Mycobacterium bovis</i> BCG	76
3.2.8.8	Drug susceptibility assay	77
3.2.8.9	Protein structure modelling.....	77
3.2.8.10	TesA-MAFP fragment interaction analysis by pull-down assay	78
3.2.8.11	ATPase activity assay	78
3.2.8.12	Trypsin digestion susceptibility assay	79
3.2.8.13	GroEL1 evaluation.....	79
3.2.8.14	GroEL1-DNA interaction analysis by electrophoretic mobility shift assay (EMSA).....	79
4	RESULTS	81
4.1	Plasmid construction	81
4.1.1	pET-15b vector modification	81
4.1.2	pGroEL1 and pGroEL1 Δ His plasmid corrections	82
4.1.3	p <i>Mt</i> GroEL1 and p <i>Mt</i> GroEL1 Δ His plasmid constructions	82
4.1.4	p <i>Mt</i> TesA plasmid construction	83
4.1.5	p <i>Mt</i> GroEL2 plasmid construction and correction	83
4.1.6	p <i>Mt</i> GroEs and p <i>Mt</i> Lsr2 plasmid constructions	84
4.1.7	p <i>Mt</i> PpsE-end and p <i>Mt</i> PpsE-C plasmid constructions	84
4.2	Protein production and purification	84
4.2.1	Preliminary experiment for protein induction and purification	84
4.2.2	Recombinant protein purification	86
4.3	Proteins quality determination	91
4.4	Methyl arachidonyl fluorophosphonate inhibits TesA activity and affects <i>M. bovis</i> BCG vancomycin susceptibility	92

4.4.1 TesA thioesterase and esterase activity assays.....	93
4.4.2 Oligomeric state of TesA	97
4.4.3 Influence of potential inhibitors on TesA activity	98
4.4.4 TesA thermal stability assay	101
4.4.5 Mass spectrometry analysis of TesA-MAFP interaction	102
4.4.6 MAFP and THL inhibit <i>M. bovis</i> BCG biofilm development	104
4.4.7 MAFP increases <i>M. bovis</i> BCG vancomycin susceptibility	106
4.4.8 Docking calculations	106
4.5 Analysis of TesA and PpsE interaction	110
4.6 Interplays between copper and <i>M. tuberculosis</i> GroEL1	110
4.6.1 Increased susceptibility to copper in biofilm culture of the $\Delta cpn60.1$ <i>M. bovis</i> BCG strain	111
4.6.2 GroEL1-copper interaction analysis by mass spectrometry.....	112
4.6.3 The effect of divalent cations on GroEL1 thermal stability.....	115
4.6.4 Protease susceptibility assay	117
4.6.5 Copper increases the GroEL1 ATPase activity	119
4.6.6 GroEL1 3D model.....	121
4.7 GroEL1 evaluation	122
4.7.1 GroEL1 evaluation assay	122
4.7.2 Characterization of GroEL1 evaluation	125
4.7.3 Recombinant GroEL1 DNA-binding activity	127
5 DISCUSSION	129
6 CONCLUSION AND PERSPECTIVES	141
7 REFERENCES.....	144
APPENDIX.....	XIV